fluvoxamine

Overview
Prescribing Info
Drug Label Annotations
Clinical Annotations
Variant Annotations
Literature
Pathways
Related To
Links
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this chemical in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    111 items
    Literature
    A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.
    Clinical pharmacology and therapeutics. 2025. Rüdesheim Simeon, Loer Helena Leonie Hanae, Feick Denise, Marok Fatima Zahra, Fuhr Laura Maria, Selzer Dominik, Teutonico Donato, Schneider Annika R P, Solodenko Juri, Frechen Sebastian, van der Lee Maaike, Moes Dirk Jan A R, Swen Jesse J, Schwab Matthias and Lehr Thorsten.
    PGx Paper Type: Methods, Phenoconversion
    Literature
    Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.
    Annual review of pharmacology and toxicology. 2025. Empey Philip E, Karnes Jason H and Johnson Julie A.
    PGx Paper Type: Implementation, Review
    Literature
    In Vitro Evaluation of CYP-Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers.
    Journal of clinical pharmacology. 2024. Iwai Megumi, Nielsen Jace, Miyagawa Mayuko, Patton Melanie, Bonate Peter L, Wang Xuegong, Wojtkowski Tomasz, Sinn Angela and Huang Jiayin.
    PGx Paper Type: Drug-Gene Interaction for Pathway
    Literature
    Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers.
    Clinical pharmacology and therapeutics. 2024. Abouir Kenza, Exquis Nadia, Gloor Yvonne, Daali Youssef and Samer Caroline Flora.
    PGx Paper Type: Allele Function, Phenoconversion
    Literature
    Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.
    Clinical pharmacology and therapeutics. 2024. Krulikas Linas, Bates Jill, Chanfreau Catherine, Coleman Heather, Dalton Shawn and Voora Deepak.
    Literature
    Serum Concentration-Dose Relationship and Modulation Factors in Children and Adolescents Treated with Fluvoxamine.
    Pharmaceutics. 2024. Taurines Regina, Kunkel Gesa, Fekete Stefanie, Fegert Jörg M, Wewetzer Christoph, Correll Christoph U, Holtkamp Kristian, Böge Isabel, Renner Tobias Johann, Imgart Hartmut, Scherf-Clavel Maike, Heuschmann Peter, Gerlach Manfred, Romanos Marcel and Egberts Karin.
    PGx Paper Type: Methods
    Literature
    Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting.
    Journal of child and adolescent psychopharmacology. 2024. Tonti Erica, Lee Yee Ming, Gruenke Nathan, Ferren Janie and Stutzman Danielle L.
    PGx Paper Type: Implementation, Phenoconversion
    Pediatric
    Literature
    Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder.
    Bipolar disorders. 2024. Xu Jin-Jie, Xiao Chunfeng, Pan Yanli, Tang Yi-Lang, Wang Mingwan, Li Sheng, Xie Gaoming, Du Jing, Ren Yanping and Wang Wei.
    PGx Paper Type: Implementation
    Literature
    Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy.
    Pharmacogenomics. 2024. Abudahab Sara, Slattum Patricia W, Price Elvin T and McClay Joseph L.
    PGx Paper Type: Review
    Literature
    Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation.
    Pharmacogenomics. 2024. Ragia Georgia, Pallikarou Myria, Manolopoulou Yiota, Vorvolakos Theofanis and Manolopoulos Vangelis G.
    PGx Paper Type: Implementation
    Literature
    The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part 2 - pharmacological properties and safety of use.
    Psychiatria polska. 2023. Janas-Kozik Małgorzata Honorata, Słopień Agnieszka, Remberk Barbara and Siwek Marcin.
    PGx Paper Type: Review, Methods, Phenoconversion
    Pediatric
    Literature
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Clinical pharmacology and therapeutics. 2023. Bousman Chad A, Stevenson James M, Ramsey Laura B, Sangkuhl Katrin, Hicks J Kevin, Strawn Jeffrey R, Singh Ajeet B, Ruaño Gualberto, Mueller Daniel J, Tsermpini Evangelia Eirini, Brown Jacob T, Bell Gillian C, Leeder J Steven, Gaedigk Andrea, Scott Stuart A, Klein Teri E, Caudle Kelly E and Bishop Jeffrey R.
    PGx Paper Type: Implementation
    Literature
    Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Pharmacogenomics. 2023. Maghari Saba, Gallo Tyler, Rivas Salvador, German Alexander, Nguyen Le Minh Q, Abbaszadegan Hamed, Zubriski Mark A, Heise Craig W and Landas Noel D.
    PGx Paper Type: Implementation
    Literature
    The impact of CYP2C19 genotype on phenoconversion by concomitant medication.
    Frontiers in pharmacology. 2023. de Jong Laura M, Boussallami Soukayna, Sánchez-López Elena, Giera Martin, Tushuizen Maarten E, Hoekstra Menno, Hawinkels Lukas J A C, Rissmann Robert, Swen Jesse J and Manson Martijn L.
    PGx Paper Type: Phenoconversion, Uses PharmGKB
    Literature
    Opportunity for pharmacogenetics testing in patients with sickle cell anemia.
    Pharmacogenomics. 2022. Gallaway Katherine A, Sakon Colleen, Ongeri Jefney, Patel Krina S, Oliver Johnathan, Patacca Heather, O'Brien Andrew Rw, Skaar Todd C and Tillman Emma M.
    PGx Paper Type: Implementation
    Literature
    Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
    European journal of human genetics : EJHG. 2022. Brouwer Jurriaan M J L, Nijenhuis Marga, Soree Bianca, Guchelaar Henk-Jan, Swen Jesse J, van Schaik Ron H N, Weide Jan van der, Rongen Gerard A P J M, Buunk Anne-Marie, de Boer-Veger Nienke J, Houwink Elisa J F, van Westrhenen Roos, Wilffert Bob, Deneer Vera H M and Mulder Hans.
    PGx Paper Type: Implementation
    Literature
    Pharmacogenetic Aspects of COVID-19 Management and Post-COVID-19 Depression Treatment with Fluvoxamine.
    Psychiatria Danubina. 2022. Dobrodeeva Vera, Abdyrahmanova Aiperi, Astafeva Darya, Smirnova Daria, Cumming Paul, De Sousa Avinash, Davydkin Igor, Yashikhina Anna, Shnayder Natalia and Nasyrova Regina.
    PGx Paper Type: Review
    Literature
    Evidence of pharmacogenetics-based fluvoxamine use as an add-on to clozapine treatment in psychiatry.
    Pharmacogenomics. 2022. Mossé Ulysse, Chaumette Boris, Wils Julien, Imbert Laurent, Lamoureux Fabien and Ferrafiat Vladimir.
    PGx Paper Type: Review
    Literature
    A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
    Pharmacology research & perspectives. 2022. Duong Janna K, Nand Romina A, Patel Aarti, Della Pasqua Oscar and Gross Annette S.
    PGx Paper Type: Population Frequency, Methods
    Literature
    Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2021. Eap C B, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl M L, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer J H, Moessner R, Mulder H, Müller D J, Reis M, Riederer P, Ruhe H G, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F and Hiemke C.
    Literature
    Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series.
    Frontiers in psychiatry. 2021. Berel Camille, Mossé Ulysse, Wils Julien, Cousin Lauriane, Imbert Laurent, Gerardin Priscille, Chaumette Boris, Lamoureux Fabien and Ferrafiat Vladimir.
    Literature
    The search for personalized antidepressant treatments: what have we learned and where are we going.
    Pharmacogenomics. 2020. Serretti Alessandro and Fabbri Chiara.
    Literature
    Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?
    Pharmacogenomics. 2020. Ruan Can-Jun and de Leon Jose.
    Literature
    Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Clinical pharmacology and therapeutics. 2019. Huth Felix, Gardin Anne, Umehara Kenichi and He Handan.
    PGx Paper Type: Methods, Drug-Gene Interaction for Pathway
    Literature
    Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder.
    Human psychopharmacology. 2018. Lisoway Amanda J, Zai Gwyneth, Tiwari Arun K, Zai Clement C, Wigg Karen, Goncalves Vanessa, Zhang Danning, Freeman Natalie, Müller Daniel J, Kennedy James L and Richter Margaret A.
    Pediatric
    Literature
    Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
    Basic & clinical pharmacology & toxicology. 2018. Murray Michael, Zhang Wei V and Edwards Robert J.
    Literature
    Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.
    Schizophrenia research. 2018. Lu Mong-Liang, Chen Tzu-Ting, Kuo Po-Hsiu, Hsu Ching-Chi and Chen Chun-Hsin.
    Literature
    The pharmacogenomics of severe traumatic brain injury.
    Pharmacogenomics. 2017. Adams Solomon M, Conley Yvette P, Wagner Amy K, Jha Ruchira M, Clark Robert Sb, Poloyac Samuel M, Kochanek Patrick M and Empey Philip E.
    Literature
    CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors.
    Pharmacogenomics. 2017. Ekhart Corine, Matic Maja, Kant Agnes, van Puijenbroek Eugène and Schaik Ron van.
    Literature
    Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Pharmacogenomics. 2017. Bahar Muh Akbar, Setiawan Didik, Hak Eelko and Wilffert Bob.
    Literature
    Pharmacogenomics of autism spectrum disorder.
    Pharmacogenomics. 2017. Brown Jacob T, Eum Seenae, Cook Edwin H and Bishop Jeffrey R.
    Literature
    Integrated patient and tumor genetic testing for individualized cancer therapy.
    Clinical pharmacology and therapeutics. 2016. Hertz D L and McLeod H L.
    Literature
    Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Clinical pharmacology and therapeutics. 2015. Hicks J K, Bishop J R, Sangkuhl K, Müller D J, Ji Y, Leckband S G, Leeder J S, Graham R L, Chiulli D L, LLerena A, Skaar T C, Scott S A, Stingl J C, Klein T E, Caudle K E, Gaedigk A and Clinical Pharmacogenetics Implementation Consortium.
    PGx Paper Type: Implementation
    Literature
    Treatment of clozapine-associated weight gain: a systematic review.
    European journal of clinical pharmacology. 2015. Whitney Z, Procyshyn R M, Fredrikson D H and Barr A M.
    Literature
    Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on.
    Pharmacopsychiatry. 2014. Gahr M, Rehbaum K and Connemann B J.
    Literature
    Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.
    The pharmacogenomics journal. 2014. Brandl E J, Tiwari A K, Zhou X, Deluce J, Kennedy J L, Müller D J and Richter M A.
    Pediatric
    Literature
    Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy.
    Medical hypotheses. 2013. Légaré Nancy, Grégoire Claire-Anne, De Benedictis Luigi and Dumais Alexandre.
    Literature
    Cytochrome P450-mediated drug metabolism in the brain.
    Journal of psychiatry & neuroscience : JPN. 2013. Miksys Sharon and Tyndale Rachel F.
    Literature
    5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
    Journal of clinical psychopharmacology. 2013. Kato Masaki, Nonen Shinpei, Serretti Alessandro, Tetsuo Shinji, Takekita Yoshiteru, Azuma Junichi and Kinoshita Toshihiko.
    Literature
    The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.
    Genetic testing and molecular biomarkers. 2012. Müller Daniel J, Brandl Eva J, Hwang Rudi, Tiwari Arun K, Sturgess Jessica E, Zai Clement C, Lieberman Jeffrey A, Kennedy James L and Richter Margaret A.
    Literature
    The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    European journal of clinical pharmacology. 2012. Azuma Junichi, Hasunuma Tomoko, Kubo Masanori, Miyatake Masaya, Koue Toshiko, Higashi Koushi, Fujiwara Tsutomu, Kitahara Sachiko, Katano Tamiki and Hara Sumiko.
    Literature
    Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
    Pharmacopsychiatry. 2011. Paulzen M, Finkelmeyer A and Grözinger M.
    Literature
    Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.
    Xenobiotica; the fate of foreign compounds in biological systems. 2011. Wang Huijuan, Kim Raymond A, Sun Dongxu, Gao Yiwen, Wang Hao, Zhu Juanli and Chen Chao.
    Literature
    CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
    Journal of psychopharmacology (Oxford, England). 2011. Suzuki Yutaro, Sugai Takuro, Fukui Naoki, Watanabe Junzo, Ono Shin, Inoue Yoshimasa, Ozdemir Vural and Someya Toshiyuki.
    Literature
    Identifying genomic and developmental causes of adverse drug reactions in children.
    Pharmacogenomics. 2010. Becker Mara L and Leeder J Steven.
    Pediatric
    Literature
    HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.
    Neuromolecular medicine. 2010. Kishi Taro, Yoshimura Reiji, Kitajima Tsuyoshi, Okochi Tomo, Okumura Takenori, Tsunoka Tomoko, Yamanouchi Yoshio, Kinoshita Yoko, Kawashima Kunihiro, Naitoh Hiroshi, Nakamura Jun, Ozaki Norio and Iwata Nakao.
    Literature
    Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.
    Pharmacogenomics. 2010. Shiroma Paulo R, Geda Yonas E and Mrazek David A.
    Literature
    Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, Ingle James N, Ames Matthew M, Loprinzi Charles L, Mrazek David P, Black John L, Weinshilboum Richard M, Hawse John R, Spelsberg Thomas C and Goetz Matthew P.
    Literature
    Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways.
    Pharmacogenomics. 2010. Morag Ayelet, Kirchheiner Julia, Rehavi Moshe and Gurwitz David.
    Literature
    Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
    BMJ (Clinical research ed.). 2010. Kelly Catherine M, Juurlink David N, Gomes Tara, Duong-Hua Minh, Pritchard Kathleen I, Austin Peter C and Paszat Lawrence F.
    Literature
    Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
    Biological & pharmaceutical bulletin. 2010. Katoh Yasuhiro, Uchida Shinya, Kawai Masayoshi, Takei Noriyoshi, Mori Norio, Kawakami Junichi, Kagawa Yoshiyuki, Yamada Shizuo, Namiki Noriyuki and Hashimoto Hisakuni.
    Literature
    Selective serotonin reuptake inhibitors pathway.
    Pharmacogenetics and genomics. 2009. Sangkuhl Katrin, Klein Teri E and Altman Russ B.
    Literature
    Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
    Clinical pharmacology and therapeutics. 2009. Anthony M, Romero K, Malone D C, Hines L E, Higgins L and Woosley R L.
    Literature
    Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.
    European journal of clinical pharmacology. 2009. Sugahara Hideyo, Maebara Chiharu, Ohtani Hisakazu, Handa Masanori, Ando Katsumi, Mine Kazunori, Kubo Chiharu, Ieiri Ichiro and Sawada Yasufumi.
    Literature
    Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.
    Pharmacotherapy. 2009. Thomas Kelan L H and Ellingrod Vicki L.
    Literature
    Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Journal of pharmacological sciences. 2009. Vezmar Sandra, Miljkovic Branislava, Vucicevic Katarina, Timotijevic Ivana, Prostran Milica, Todorovic Zoran and Pokrajac Milena.
    Literature
    A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2009. Hori Hikaru, Yoshimura Reiji, Ueda Nobuhisa, Ikenouchi-Sugita Atsuko, Umene-Nakano Wakako and Nakamura Jun.
    Literature
    Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.
    Therapeutic drug monitoring. 2008. Watanabe Junzo, Suzuki Yutaro, Fukui Naoki, Sugai Takuro, Ono Shin, Inoue Yoshimasa and Someya Toshiyuki.
    Literature
    Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety.
    Pharmacogenomics. 2008. Kronenberg Sefi, Frisch Amos, Rotberg Beni, Carmel Miri, Apter Alan and Weizman Abraham.
    Pediatric
    Literature
    Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
    British journal of clinical pharmacology. 2008. Bijl Monique J, Visser Loes E, Hofman Albert, Vulto Arnold G, van Gelder Teun, Stricker Bruno H Ch and van Schaik Ron H N.
    Literature
    Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.
    The Journal of clinical psychiatry. 2007. Castberg Ingrid, Skogvoll Eirik and Spigset Olav.
    Pediatric
    Literature
    Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine.
    Xenobiotica; the fate of foreign compounds in biological systems. 2007. Miura M and Ohkubo T.
    Literature
    Metabolic drug interactions with newer antipsychotics: a comparative review.
    Basic & clinical pharmacology & toxicology. 2007. Spina Edoardo and de Leon Jose.
    Literature
    Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Suzuki Yutaro, Sawamura Kazushi and Someya Toshiyuki.
    Literature
    Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
    Neuropsychobiology. 2006. Kato Masaki, Fukuda Tsuyoshi, Wakeno Masataka, Fukuda Kazuhiro, Okugawa Gaku, Ikenaga Yuka, Yamashita Megumi, Takekita Yoshiteru, Nobuhara Kenji, Azuma Junichi and Kinoshita Toshihiko.
    Literature
    Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    International clinical psychopharmacology. 2005. Kato Masaki, Ikenaga Yuka, Wakeno Masataka, Okugawa Gaku, Nobuhara Kenji, Fukuda Tsuyoshi, Fukuda Kazuhiro, Azuma Junichi and Kinoshita Toshihiko.
    Literature
    Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2004. Serretti Alessandro, Cusin Cristina, Rossini David, Artioli Paola, Dotoli Danilo and Zanardi Raffaella.
    Literature
    Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
    Journal of clinical psychopharmacology. 2004. Eap Chin B, Bender Stefan, Jaquenoud Sirot E, Cucchia Gianni, Jonzier-Perey Michèle, Baumann Pierre, Allorge Delphine and Broly Franck.
    Literature
    Some aspects of genetic polymorphism in the biotransformation of antidepressants.
    Therapie. 2004. Brøsen Kim.
    Literature
    The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.
    The pharmacogenomics journal. 2004. Suzuki Y, Sawamura K and Someya T.
    Literature
    Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Therapeutic drug monitoring. 2003. Gerstenberg Gisa, Aoshima Toshiaki, Fukasawa Takashi, Yoshida Keizo, Takahashi Hitoshi, Higuchi Hisashi, Murata Yoshiko, Shimoyama Ritsuko, Ohkubo Tadashi, Shimizu Tetsuo and Otani Koichi.
    Literature
    Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Psychopharmacology. 2003. Gerstenberg Gisa, Aoshima Toshiaki, Fukasawa Takashi, Yoshida Keizo, Takahashi Hitoshi, Higuchi Hisashi, Murata Yoshiko, Shimoyama Ritsuko, Ohkubo Tadashi, Shimizu Tetsuo and Otani Koichi.
    Literature
    Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
    Drug metabolism and disposition: the biological fate of chemicals. 2003. Yao Caiping, Kunze Kent L, Trager William F, Kharasch Evan D and Levy René H.
    Literature
    Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
    Pharmacogenetics. 2003. Yu Ai-Ming, Idle Jeffrey R, Byrd Linda G, Krausz Kristopher W, Küpfer Adrian and Gonzalez Frank J.
    Literature
    CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.
    European journal of clinical pharmacology. 2003. Ohara Koichi, Tanabu Shigeru, Ishibashi Kazuhisa, Ikemoto Keiko, Yoshida Kimiko and Shibuya Haruo.
    Literature
    No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002. Takahashi Hitoshi, Yoshida Keizo, Ito Kenich, Sato Kazuhiro, Kamata Mitsuhiro, Higuchi Hisashi, Shimizu Tetsuo, Ito Kunihiko, Inoue Kazuyuki, Tezuka Takehiko, Suzuki Toshio, Ohkubo Tadashi and Sugawara Kazunobu.
    Literature
    A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine.
    Psychiatry research. 2002. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K and Otani K.
    Literature
    Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Clinical pharmacology and therapeutics. 2002. Christensen Magnus, Tybring Gunnel, Mihara Kazuo, Yasui-Furokori Norio, Carrillo Juan Antonio, Ramos Sara I, Andersson Katarina, Dahl Marja-Liisa and Bertilsson Leif.
    Literature
    The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
    The Journal of pharmacology and experimental therapeutics. 2002. Thomas Dierk, Gut Bernd, Wendt-Nordahl Gunnar and Kiehn Johann.
    Literature
    Med-psych drug-drug interactions update.
    Psychosomatics. 2002. Armstrong Scott C, Cozza Kelly L and Oesterheld Jessica R.
    Literature
    Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
    The pharmacogenomics journal. 2002. Di Bella D, Erzegovesi S, Cavallini M C and Bellodi L.
    Literature
    Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
    Drug metabolism and drug interactions. 2002. Jan Michael W, ZumBrunnen Troy L, Kazmi Yusuf R, VanDenBerg Chad M, Desai Hiral D, Weidler Donald J and Flockhart David A.
    Literature
    Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.
    Journal of clinical psychopharmacology. 2001. Ozdemir V, Kalow W, Okey A B, Lam M S, Albers L J, Reist C, Fourie J, Posner P, Collins E J and Roy R.
    Literature
    The major fluvoxamine metabolite in urine is formed by CYP2D6.
    European journal of clinical pharmacology. 2001. Spigset O, Axelsson S, Norström A, Hägg S and Dahlqvist R.
    Literature
    Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Biological psychiatry. 2001. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D and Smeraldi E.
    Literature
    Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.
    Molecular psychiatry. 2001. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R and Smeraldi E.
    Literature
    Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes.
    European journal of clinical pharmacology. 2001. Facciolá G, Hidestrand M, von Bahr C and Tybring G.
    PGx Paper Type: Drug-Gene Interaction for Pathway
    Literature
    CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    Drug metabolism and disposition: the biological fate of chemicals. 2000. Hesse L M, Venkatakrishnan K, Court M H, von Moltke L L, Duan S X, Shader R I and Greenblatt D J.
    Literature
    Science, medicine, and the future: Pharmacogenetics.
    BMJ (Clinical research ed.). 2000. Wolf C R, Smith G and Smith R L.
    Literature
    Increased bioavailability of oral melatonin after fluvoxamine coadministration.
    Clinical pharmacology and therapeutics. 2000. Härtter S, Grözinger M, Weigmann H, Röschke J and Hiemke C.
    Literature
    Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    European journal of clinical pharmacology. 1999. Hemeryck A, De Vriendt C and Belpaire F M.
    Literature
    Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
    Molecular psychiatry. 1998. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J and Catalano M.
    Literature
    Differences in interactions of SSRIs.
    International clinical psychopharmacology. 1998. Brøsen K.
    Literature
    Non-linear fluvoxamine disposition.
    British journal of clinical pharmacology. 1998. Spigset O, Granberg K, Hägg S, Söderström E and Dahlqvist R.
    Literature
    Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    European journal of clinical pharmacology. 1997. Spigset O, Granberg K, Hägg S, Norström A and Dahlqvist R.
    Literature
    Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Clinical pharmacokinetics. 1996. Baumann P.
    Literature
    Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
    Clinical pharmacology and therapeutics. 1996. Carrillo J A, Dahl M L, Svensson J O, Alm C, Rodríguez I and Bertilsson L.
    Literature
    Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
    Pharmacological research. 1995. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D and Bizouard P.
    Literature
    Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    Journal of clinical psychopharmacology. 1995. von Moltke L L, Greenblatt D J, Court M H, Duan S X, Harmatz J S and Shader R I.
    Literature
    Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update.
    International journal of psychiatry in medicine. 1995. Shen W W.
    Literature
    Clinical pharmacokinetics of fluvoxamine.
    Clinical pharmacokinetics. 1994. Perucca E, Gatti G and Spina E.
    Literature
    Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?
    Therapie. 1992. Bonnet P, Vandel S, Nezelof S, Sechter D and Bizouard P.
    Literature
    CPIC® Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 – CPIC
    PGx Paper Type: Implementation
    Literature
    Clinical Trial: A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection (STOP COVID)
    Literature
    DailyMed - FLUVOXAMINE MALEATE capsule, extended release
    Literature
    Drugs@FDA: Drug Product fluvoxamine maleate (Fluvoxamine maleate), NDA021519, Bryant Ranch Prepack
    Literature
    Drugs@HCSC: Drug Product TEVA-FLUVOXAMINE (fluvoxamine), Teva Canada Limited
    Literature
    Dutch Pharmacogenetics Working Group Guidelines August 2019
    Literature
    Dutch Pharmacogenetics Working Group Guidelines November 2018
    Literature
    P450 Drug Interaction Table (Flockhart Table ™)
    Literature
    Swissmedic label for fluvoxamine